[MarketWatch] Sovaldi pricing raises debate over drug costs

WASHINGTON (MarketWatch) — With the California-based drug manufacturer Gilead Sciences planning to roll out another hepatitis C medication, academics said Wednesday that policy changes are needed in the costly drug market so the interests of patients, health insurers and pharmaceutical companies align.

At a Brookings Institution and the University of Southern California’s Schaeffer Center for Health Policy & Economics forum, USC’s Darius Lakdawalla argued that the cost and benefits of some drugs don’t match up.